TransCode Therapeutics, Inc. (RNAZ)

NASDAQ

$1,71

$+0,04

(+2,45%)

Regular Market

TransCode Therapeutics, Inc. (RNAZ) Live Price Chart

Last updated: ⁦2026-10-13 18:53:20⁩. Prices reflect the latest regular market data. Stock price data is sourced from Massive.

Summary

TransCode Therapeutics, Inc. (RNAZ) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1,71, with a market capitalisation of $31,49M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1,52 to $15,90. This page covers its latest market performance, valuation, price trends and company information.

Key Market Data

Market Cap	$31,49M
Open	$1,67
Day's High	$5.174.400,00
Day's Low	$1,52
Previous Close	$1,63
Volume	45,25K
Average Volume	51,87K
P/E Ratio	--
52-Week High	$15,90
52-Week Low	$1,52
Dividend Yield	--
Earnings Date	--

TransCode Therapeutics, Inc. (RNAZ) Stock Price Today

TransCode Therapeutics, Inc. (RNAZ) is currently trading at $1,71 as of 2026-10-13 18:51:00, up 4,91% ($0,08) from the previous close of $1,63

During today's regular trading session, RNAZ has traded between $1,52 and $5.174.400,00, with a trading volume of 45,25K shares. The current price is near the lower end of today's range.

TransCode Therapeutics, Inc. (RNAZ) 7-Day Stock Price Change

Over the past seven days, TransCode Therapeutics, Inc. (RNAZ) moved from $1,57 to $1,71, representing a gain of 8,92% ($0,14).

The stock traded between $1,55 and $1,95 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.

The average daily volume was 43,17 thousand shares, down versus the previous seven-day period, indicating lower trading activity.

RNAZ 52-Week Price Position

Position in Range: 1,3%

52W Low$1,52

52W High$15,90

RNAZ is currently trading at $1,71, placing it 1,3% of the way from its 52-week low of $1,52 to its 52-week high of $15,90. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.

What is TransCode Therapeutics, Inc. (RNAZ)?

TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.

TransCode Therapeutics, Inc. Information

Industry	PHARMACEUTICAL PREPARATIONS
Employees	12
Exchange	NASDAQ
Company Website	https://www.transcodetherapeutics.com

How to Buy TransCode Therapeutics, Inc. (RNAZ) Stock on MEXC

Eligible investors can buy real shares of TransCode Therapeutics, Inc. (RNAZ) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.

Step 1: Open and Verify Your RealStocks Account

Log in to the MEXC App, go to Trade → RealStocks, and select Open Account. Complete the required account-opening and identity verification process with MEXC's partner licenced broker.

Step 2: Transfer USDT to Your RealStocks Account

Go to Wallets → RealStocks and transfer USDT from your Spot Account to your RealStocks Account. RealStocks are quoted in USD, while account funding can be completed using USDT.

Step 3: Search for RNAZ and Place Your Order

Open the RealStocks trading page and search for RNAZ. Select a market or limit order, enter the price and quantity as required, review the order details, and submit your order. Once filled, the corresponding real shares will be held in your RealStocks Account.

Frequently Asked Questions (FAQ)

1.What is TransCode Therapeutics, Inc. (RNAZ) stock price today?

TransCode Therapeutics, Inc. (RNAZ) is currently trading at $ 1,71, up 4,91% ($0,08) from the previous close of $ 1,63. Intraday prices update in real time during regular trading hours.

2.Is RNAZ stock going up or down today?

As of 2026-10-13 18:51:00, RNAZ is trading at $ 1,71, up 4,91% ($0,08) from its previous close of $ 1,63. The stock has traded between $ 1,52 and $ 5.174.400,00 during today’s regular session. Past price movements do not guarantee future results.

3.What is RNAZ pre-market price?

As of 2026-10-13 18:51:00, RNAZ is trading at $ 1,67 in pre-market trading, up 2,15% ($0,04) from the previous close of $ 1,63. Pre-market prices reflect trading activity before the regular session opens and may experience lower liquidity and higher volatility.

4.What is RNAZ after-hours price?

As of 2026-10-13 18:51:00, RNAZ is trading at $ 1,65 in after-hours trading, up 0,92% ($0,02) from the regular-session close of $ 1,63. After-hours prices may differ from the regular session’s opening price due to lower liquidity and wider bid-ask spreads.

5.Is RNAZ stock trading now?

RNAZ trades on the NASDAQ exchange during regular hours, Monday through Friday, 9:30 AM to 4:00 PM ET, excluding public holidays. Pre-market and after-hours trading are also available through select brokers outside these hours.

6.Where does RNAZ sit relative to its 52-week high and low?

Over the past 52 weeks, RNAZ has traded between a low of $ 1,52 and a high of $ 15,90. At $ 1,71, the stock is positioned 1,3% of the way from its 52-week low to its 52-week high, providing context for its current price within the one-year trading range.

7.What sector is TransCode Therapeutics, Inc. in?

TransCode Therapeutics, Inc. (RNAZ) operates in the PHARMACEUTICAL PREPARATIONS sector. Sector classification helps investors compare it with companies exposed to similar market trends and competitive conditions.

8.What is TransCode Therapeutics, Inc.'s market capitalisation and where is it listed?

TransCode Therapeutics, Inc. is listed on the NASDAQ exchange with a market capitalisation of $ 31,49M. Market cap reflects the total market value of all outstanding shares and is commonly used to classify stocks by size.

9.How is RNAZ valued in terms of P/E ratio and EPS?

RNAZ trades at a P/E ratio of --, based on trailing-twelve-month EPS of $ -2,73. P/E ratio compares the stock price to earnings per share and is a common starting point for assessing valuation relative to peers.

10.Does TransCode Therapeutics, Inc. pay a dividend?

TransCode Therapeutics, Inc. pays an indicated annual cash dividend of $ 0,00 per share, with a current dividend yield of 0,00% based on the latest share price. Dividend policies are subject to change at the board's discretion.